| Compound Information | SONAR Target prediction |
| Name: | THIORIDAZINE HYDROCHLORIDE |
| Unique Identifier: | SPE01500575 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 379.823 g/mol |
| X log p: | 16.127 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 57.08 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 4 |
| Canonical Smiles: | Cl.CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1 |
| Source: | synthetic |
| Therapeutics: | antipsychotic |
| Generic_name: | Thioridazine |
| Chemical_iupac_name: | 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA451666 |
| Kegg_compound_id: | C07133 |
| Drugbank_id: | APRD00596 |
| Melting_point: | 73 oC |
| H2o_solubility: | 0.0336 mg/L |
| Logp: | 6.552 |
| Isoelectric_point: | 9.5 |
| Cas_registry_number: | 50-52-2 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C50522&Index=0&Type=Mass&Large=on |
| Drug_category: | Antipsychotics; Dopamine Antagonists; Phenothiazines; ATC:N05AC02 |
| Indication: | For the treatment of schizophrenia and generalized anxiety disorder. |
| Pharmacology: | Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the
management of schizophrenia and other psychotic disorders. Thioridazine has not been
shown effective in the management of behaviorial complications in patients with
mental retardation. |
| Mechanism_of_action: | Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the
brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and
hypophyseal hormones and is believed to depress the reticular activating system thus
affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and
emesis. |
| Organisms_affected: | Humans and other mammals |
